KR102943465B1 - 혈액암의 치료를 위한 이중특이적 CD123 x CD3 디아바디 - Google Patents

혈액암의 치료를 위한 이중특이적 CD123 x CD3 디아바디

Info

Publication number
KR102943465B1
KR102943465B1 KR1020217014961A KR20217014961A KR102943465B1 KR 102943465 B1 KR102943465 B1 KR 102943465B1 KR 1020217014961 A KR1020217014961 A KR 1020217014961A KR 20217014961 A KR20217014961 A KR 20217014961A KR 102943465 B1 KR102943465 B1 KR 102943465B1
Authority
KR
South Korea
Prior art keywords
gene
signature
expression
genes
regarding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217014961A
Other languages
English (en)
Korean (ko)
Other versions
KR20210110567A (ko
Inventor
잔 케네쓰 데이빗슨
사라 처취
세르지오 루틀러
Original Assignee
마크로제닉스, 인크.
엔에스 윈드 다운 코., 인크.
노팅엄 트렌트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크로제닉스, 인크., 엔에스 윈드 다운 코., 인크., 노팅엄 트렌트 유니버시티 filed Critical 마크로제닉스, 인크.
Publication of KR20210110567A publication Critical patent/KR20210110567A/ko
Application granted granted Critical
Publication of KR102943465B1 publication Critical patent/KR102943465B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020217014961A 2018-10-30 2019-10-29 혈액암의 치료를 위한 이중특이적 CD123 x CD3 디아바디 Active KR102943465B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752659P 2018-10-30 2018-10-30
US62/752,659 2018-10-30
US201862769078P 2018-11-19 2018-11-19
US62/769,078 2018-11-19
US201962878368P 2019-07-25 2019-07-25
US62/878,368 2019-07-25
PCT/US2019/058616 WO2020092404A1 (en) 2018-10-30 2019-10-29 Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies

Publications (2)

Publication Number Publication Date
KR20210110567A KR20210110567A (ko) 2021-09-08
KR102943465B1 true KR102943465B1 (ko) 2026-03-25

Family

ID=70464448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217014961A Active KR102943465B1 (ko) 2018-10-30 2019-10-29 혈액암의 치료를 위한 이중특이적 CD123 x CD3 디아바디

Country Status (13)

Country Link
US (1) US20210395374A1 (enExample)
EP (1) EP3873606A4 (enExample)
JP (2) JP7551066B2 (enExample)
KR (1) KR102943465B1 (enExample)
CN (3) CN113286633A (enExample)
AU (1) AU2019371243A1 (enExample)
BR (1) BR112021008283A2 (enExample)
CA (1) CA3118081A1 (enExample)
IL (1) IL282827A (enExample)
MX (1) MX2021004868A (enExample)
SG (1) SG11202104367RA (enExample)
WO (1) WO2020092404A1 (enExample)
ZA (1) ZA202102775B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022025834A2 (pt) * 2020-06-18 2023-01-10 Macrogenics Inc Método para determinar se um paciente seria um respondedor adequado ao uso de uma molécula biespecífica cd123 x cd3 para tratar uma malignidade hematológica e método de tratamento de uma malignidade hematológica
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
TW202241469A (zh) * 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
WO2023092119A2 (en) * 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
EP4499683A1 (en) * 2022-03-29 2025-02-05 NGM Biopharmaceuticals, Inc. Ilt3 and cd3 binding agents and methods of use thereof
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
KR20250134857A (ko) * 2024-03-05 2025-09-12 사회복지법인 삼성생명공익재단 비소세포폐암 환자의 면역 관문 억제제에 대한 반응성을 예측하는 방법, 장치, 및 컴퓨터프로그램
CN120866362B (zh) * 2025-07-15 2026-03-31 郑州大学第一附属医院 过表达ifitm2基因的car-t细胞、构建方法及其在免疫细胞疗法中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018015340A1 (en) 2016-07-18 2018-01-25 Sanofi Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005201935B2 (en) * 2004-05-06 2012-04-26 Veridex, Llc Prognostic for hematological malignancy
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
US20160272720A1 (en) * 2013-11-06 2016-09-22 Memorial Sloan-Kettering Cancer Center Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes
PL3119807T3 (pl) * 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
JP2018538247A (ja) 2015-10-23 2018-12-27 第一三共株式会社 Ａｍｌを処置することに用いるための医薬組成物およびそれを必要とする対象においてａｍｌを処置する方法
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018015340A1 (en) 2016-07-18 2018-01-25 Sanofi Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Also Published As

Publication number Publication date
CN113286633A (zh) 2021-08-20
JP2024178163A (ja) 2024-12-24
JP7551066B2 (ja) 2024-09-17
CN119236065A (zh) 2025-01-03
KR20210110567A (ko) 2021-09-08
MX2021004868A (es) 2021-09-08
WO2020092404A1 (en) 2020-05-07
SG11202104367RA (en) 2021-05-28
BR112021008283A2 (pt) 2021-09-14
IL282827A (en) 2021-06-30
US20210395374A1 (en) 2021-12-23
EP3873606A4 (en) 2022-10-26
JP2022513402A (ja) 2022-02-07
EP3873606A1 (en) 2021-09-08
ZA202102775B (en) 2022-03-30
WO2020092404A8 (en) 2021-05-20
CA3118081A1 (en) 2020-05-07
CN119280393A (zh) 2025-01-10
AU2019371243A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
KR102943465B1 (ko) 혈액암의 치료를 위한 이중특이적 CD123 x CD3 디아바디
US11045546B1 (en) Methods of treating coronavirus infection
AU2023201367B2 (en) Chimeric receptor T cell treatment using characteristics of the tumor microenvironment
TW202216175A (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
US20240254235A1 (en) Compositions and methods for treating lung cancer
Li et al. The targeting effect of cetuximab combined with PD-L1 blockade against EGFR-expressing tumors in a tailored CD16-CAR T-Cell reporter system
RU2837616C2 (ru) БИСПЕЦИФИЧНЫЕ ДИАТЕЛА CD123 х CD3 ДЛЯ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКИХ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
US20230220087A1 (en) Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies
HK40095144A (zh) 双特异性cd123 x cd3双抗体用於治疗血液系统恶性肿瘤的用途
US20230060292A1 (en) Split chimeric antigen receptors and methods of use
Qualls et al. High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19
EP4549572A1 (en) Fusion protein
WO2026015853A1 (en) Enhancing activity and persistence of car-nk cells for the treatment of cancer and autoimmune diseases
HK40123134A (zh) 使用肿瘤微环境的特徵的嵌合受体t细胞治疗
HK40044133A (en) Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
HK40011995A (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)